With regard to targeting neoantigens in lower-grade glioma, mutant isocitrate dehydrogenase type 1 (IDH1) is carried by more than 70% of diffuse grade II and III gliomas,36 and targeting IDH1 by peptide vaccination has shown efficacy.37 Here, IDH1 is linked to central nervous system cancer.